Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer

In this study, an initial Phase I component of six patients will be conducted to monitor for
potential toxicities as this wil be the initial adult experience of fenretinide (4-HPR)
given together with ketoconazole

Inclusion Criteria:

- Recurrent epithelial ovarian cancer or primary peritoneal carcinoma that can be
platinum sensitive or platinum resistant

- SWOG Performance Status 0-2

- Previously received a platinum and paclitaxel containing regimen

- Projected Life Expectancy of at least 3 months

- Adequate bone marrow function

- Adequate organ function

- Must have received at least 1 prior salvage regimen for recurrent ovarian cancer

- Recovery from acute toxicities from surgery, radiation or chemotherapy

- At least 3 weeks from last therapy

Exclusion Criteria:

- Prior fenretinide oral capsule use allowed. If prior IV fenretinide use, must contact
study chair for eligibility

- Second malignancy within last 5 years

- Use of concomitant antioxidants, such as vitamin C or E

- Untreated or symptomatic brain metastases

- History of hypertriglyceride levels > 200 mg/dl; triglyceride levels < 200 and
receiving treatment are okay.

- Use of certain medications is prohibited - contact study coordinator for information